Therapeutic uses of PSMA targeted bispecific polypeptides

TW202641842APending Publication Date: 2026-10-16VIR BIOTECHNOLOGY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114150338
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-19
Filing Date
2025-12-19
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080772_001
    Figure TWG2TA001080772_001
  • Figure TWG2TA001080772_002
    Figure TWG2TA001080772_002
  • Figure TWG2TA001080772_003
    Figure TWG2TA001080772_003
Patent Text Reader

Abstract

Provided are compositions and methods for treating cancers, in particular those characterized with PSMA expression such as prostate cancer. The compositions include a conditionally-activatable XTENylated Protease-Activated bispecific T Cell Engager targeting PSMA (PSMA-XPAT) that remain inactive until activated by proteases present in tumor microenvironment. The PSMA-XPAT exhibited exceptional safety profiles even at high doses and were efficacious in cancer patients resistant to even multiple lines of prior therapies.
Need to check novelty before this filing date? Find Prior Art